For today’s edition of our upgrade list, we used our website’s advanced screening functions to search for UPGRADES to BUY or STRONG BUY with complete forecast and valuation data. They are presented by one-month forecast return. Mallinckrodt Plc (MNK) is our top-rated upgrade this week and it is a STRONG BUY. The rest of the components on our list are BUY-rated companies.
|
Ticker |
Company Name |
Market Price |
Valuation |
Last 12-M Return |
1-M Forecast Return |
1-Yr Forecast Return |
P/E Ratio |
Sector Name |
|
MNK |
MALLINCKRODT PL |
65.91 |
-17.98% |
15.39% |
1.16% |
13.92% |
8.00 |
Medical |
|
HZNP |
HORIZON PHARMA |
20.3 |
13.21% |
12.84% |
0.71% |
8.54% |
11.03 |
Medical |
|
MRLN |
MARLIN BUS SVCS |
19.5 |
2.62% |
13.84% |
0.69% |
8.26% |
14.03 |
Finance |
|
DECK |
DECKERS OUTDOOR |
60.17 |
23.74% |
21.26% |
0.64% |
7.69% |
14.56 |
Consumer Discretionary |
|
FL |
FOOT LOCKER INC |
71.53 |
3.37% |
15.04% |
0.62% |
7.42% |
15.58 |
Retail-Wholesale |
Below is today’s data on Mallinckrodt Plc. (MNK):
Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.Â
VALUENGINE RECOMMENDATION: ValuEngine updated its recommendation from BUY to STRONG BUY for MALLINCKRODT PLC on 2016-11-11. Based on the information we have gathered and our resulting research, we feel that MALLINCKRODT PLC has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE P/E Ratio and Company Size.Â
